Page 7 - Flipbook
P. 7
Algorithm for first line chemotherapy for metastatic UC
from July 2018
Number PD-L1 biomarker Response in PD- Overall survival
L1 +ve In PD-L1 +ve
atezolizumab 32 SP142 (>5% 28% 12.3 months
IC) (14-47) (6-NE) Balar et al
Lancet 2016
pembrolizumab 110 22C3 CPS 47% 18.5 months and17
10% (38-57) (12.2-28.5)
